sum-101
Vaccineexperimental
Clinical trial activity
2 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Apr 1, 2025 (NCT06618885)
Timeline
2020s
- Jan 1, 2025
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Plasmodium malariaeImmunity, active
Plasmodium malariae immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07124156 | Phase 1 | Mar 20, 2026 | European Vaccine Initiative (EVI), Heidelberg, Germany, Ifakara Health Institute, Luxembourg Institute of Health |
| NCT06618885 | Phase 1 | Apr 1, 2025 | European Vaccine Initiative (EVI), Heidelberg, Germany, Groupe de Recherche Action en Santé (GRAS), Burkina Faso, Luxembourg Institute of Health |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| European Vaccine Initiative (EVI), Heidelberg, Germany | Government | 2 | 2 | 1 | 2025 |
| Luxembourg Institute of Health | Academic/Hospital | 2 | 0 | 1 | 2025 |
| Groupe de Recherche Action en Santé (GRAS), Burkina Faso | Academic/Hospital | 1 | 0 | 1 | 2025 |
| Ifakara Health Institute | Academic/Hospital | 1 | 0 | 1 | 2026 |
4 organizations
Page 1 / 1